Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Atara Biotherapeutics Inc (ATRA)

NASDAQ
Currency in USD
Disclaimer
0.69
-0.01(-0.86%)
Closed
After Hours
0.71+0.02(+2.78%)
Earnings results expected today
Fair Value
Unlock Value
Day's Range
0.650.72
52 wk Range
0.203.08
Prev. Close
0.7
Open
0.66
Day's Range
0.65-0.72
52 wk Range
0.2-3.08
Volume
1,188,219
Average Vol. (3m)
3,147,639
1-Year Change
-75.52%
Shares Outstanding
101,922,250
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
4.82
Upside +598.55%

People Also Watch

5.89
SOUN
-0.67%
0.2200
NVIVQ
+4.61%
1,010.03
SMCI
-1.30%
2.050
BBAI
-4.65%
4.32
GTHX
-3.36%
How do you feel today about ATRA?
Vote to see community's results!
or

Atara Biotherapeutics Inc Company Profile

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through the incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Its pipeline products include Tab-cel, ATA188, ATA2271, ATA3271, and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is used for the treatment of multiple sclerosis.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.